Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,909 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K, Migueles SA, Huang J, Bolkhovitinov L, Stuccio S, Griesman T, Pullano AA, Kang BH, Ishida E, Zimmerman M, Kashyap N, Martins KM, Stadlbauer D, Pederson J, Patamawenu A, Wright N, Shofner T, Evans S, Liang CJ, Candia J, Biancotto A, Fantoni G, Poole A, Smith J, Alexander J, Gurwith M, Krammer F, Connors M. Matsuda K, et al. Among authors: smith j. J Clin Invest. 2021 Mar 1;131(5):e140794. doi: 10.1172/JCI140794. J Clin Invest. 2021. PMID: 33529172 Free PMC article. Clinical Trial.
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.
Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M. Matsuda K, et al. Among authors: smith j. Sci Immunol. 2019 Apr 19;4(34):eaau2710. doi: 10.1126/sciimmunol.aau2710. Sci Immunol. 2019. PMID: 31004012 Clinical Trial.
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J. Malherbe DC, et al. Among authors: smith j. J Virol. 2018 Jan 2;92(2):e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15. J Virol. 2018. PMID: 29093095 Free PMC article.
Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.
Vang L, Morello CS, Mendy J, Thompson D, Manayani D, Guenther B, Julander J, Sanford D, Jain A, Patel A, Shabram P, Smith J, Alexander J. Vang L, et al. Among authors: smith j. PLoS Negl Trop Dis. 2021 Mar 12;15(3):e0009195. doi: 10.1371/journal.pntd.0009195. eCollection 2021 Mar. PLoS Negl Trop Dis. 2021. PMID: 33711018 Free PMC article.
Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.
Thompson D, Guenther B, Manayani D, Mendy J, Smith J, Espinosa DA, Harris E, Alexander J, Vang L, Morello CS. Thompson D, et al. Among authors: smith j. PLoS Negl Trop Dis. 2022 Jul 6;16(7):e0010588. doi: 10.1371/journal.pntd.0010588. eCollection 2022 Jul. PLoS Negl Trop Dis. 2022. PMID: 35793354 Free PMC article.
Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.
Espinosa D, Mendy J, Manayani D, Vang L, Wang C, Richard T, Guenther B, Aruri J, Avanzini J, Garduno F, Farness P, Gurwith M, Smith J, Harris E, Alexander J. Espinosa D, et al. Among authors: smith j. EBioMedicine. 2018 Jan;27:61-70. doi: 10.1016/j.ebiom.2017.12.010. Epub 2017 Dec 12. EBioMedicine. 2018. PMID: 29269041 Free PMC article.
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, Alexander J, Ledgerwood JE, de Lame PA, Royalty Tredo S, Warfield KL, Bedell L. Bennett SR, et al. Among authors: smith j. Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13. Lancet Infect Dis. 2022. PMID: 35709798 Clinical Trial.
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
Alexander J, Mendy J, Vang L, Avanzini JB, Garduno F, Manayani DJ, Ishioka G, Farness P, Ping LH, Swanstrom R, Parks R, Liao HX, Haynes BF, Montefiori DC, LaBranche C, Smith J, Gurwith M, Mayall T. Alexander J, et al. Among authors: smith j. PLoS One. 2013 Dec 3;8(12):e82380. doi: 10.1371/journal.pone.0082380. eCollection 2013. PLoS One. 2013. PMID: 24312658 Free PMC article.
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.
Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK. Morse MA, et al. Among authors: smith j. J Clin Invest. 2010 Sep;120(9):3234-41. doi: 10.1172/JCI42672. Epub 2010 Aug 2. J Clin Invest. 2010. PMID: 20679728 Free PMC article.
32,909 results
You have reached the last available page of results. Please see the User Guide for more information.